Mission / Vision
The International Consortium on Anti-Virals (ICAV)/ Consortium International sur les Thérapies Antivirales (CITAV): is a Canadian ‘Not-For-profit’ drug development company founded in 2004 to discover and develop novel anti-viral therapies for neglected and emerging diseases, and to ensure their global accessibility to all those in need.
ICAV recognizes the need for the international community to establish a capability to detect, contain and treat diseases and pandemics promptly in both the developed and developing worlds. ICAV supports the development of therapies for such viruses as Influenza, Dengue, HIV, Hepatitis, Lassa, Yellow Fever, Chikungunya, Ebola and Marburg, and other infectious viral diseases.
To empower countries in every continent to become self-sufficient in supplying affordable anti-viral drugs to their people.
Through the international collaboration of scientists, governments and industry, ICAV accelerates the discovery and development of novel anti-viral therapies. ICAV's mandate is to ensure the delivery of these therapies to those most in need.
Why ICAV is Needed
- Millions of people die from viral diseases every year. Most of those affected cannot afford therapies.
- The global community is unequipped to deal with the next pandemic.
- Pharmaceutical companies have failed to fill the anti-viral gap.
- ICAV is accelerating the development of novel, effective and accessible anti-viral therapies.
- ICAV will ensure that its therapies are available at cost or for free in lower- and middle-income countries.
- ICAV is developing therapies that will provide the first line of defence in the next pandemic situation.